PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12.38%
Both yoy net incomes decline, with GNPX at -11.23%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-27.15%
Both reduce yoy D&A, with GNPX at -2.36%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-5631.45%
Negative yoy deferred tax while GNPX stands at 100.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
0.93%
Less SBC growth vs. GNPX's 27.06%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-32.67%
Negative yoy working capital usage while GNPX is 80.24%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
107.56%
A yoy AP increase while GNPX is negative at -44068.07%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-665.24%
Negative yoy usage while GNPX is 160.06%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
5631.45%
Some yoy increase while GNPX is negative at -100.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-36.10%
Both yoy CFO lines are negative, with GNPX at -0.34%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
78.08%
Some CapEx rise while GNPX is negative at -24.61%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.08%
We have mild expansions while GNPX is negative at -38.98%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
66.67%
Debt repayment growth of 66.67% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
210.14%
Stock issuance far above GNPX's 166.36%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.